Prospective Evaluation of Irreversible Electroporation With Clustered Electrodes as a Novel Palliative Approach for Locally Advanced Pancreatic Cancer
Authors:
- Joon Ho KwonJKJoon Ho Kwon
- Man-Deuk KimMKMan-Deuk Kim
- Maher Salamah AlanaziMAMaher Salamah Alanazi
- Jiwon SukJSJiwon Suk
- Seung JeongSJSeung Jeong
- Seungmin BangSBSeungmin Bang
- Moon Jae ChungMCMoon Jae Chung
- Ho Kyoung HwangHHHo Kyoung Hwang
- Seung Soo HongSHSeung Soo Hong
- Kichang HanKHKichang Han
- Gyoung Min KimGKGyoung Min Kim
- Jong Yun WonJWJong Yun Won
Open Access
- 1 January 2026
- journal article
- Published by XMLink in Korean Journal of Radiology
- Vol. 27 (2) , 152-160
Abstract
This study aimed to evaluate the feasibility, safety, and oncologic outcomes of irreversible electroporation (IRE) using a clustered electrode in patients with locally advanced pancreatic cancer (LAPC). In this single-center prospective cohort study, 13 patients with LAPC (median age, 60 years; range, 48–78 years) underwent clustered electrode IRE between September 2022 and September 2024. Patient characteristics, procedural details, and clinical outcomes were recorded. Endpoints included technical success, procedure-related complications, overall survival (OS), and progression-free survival (PFS). Tumors were located in the pancreatic head in four patients (30.8%) and in the body/tail in nine (69.2%). The median tumor size was 2.4 cm (1.5–4.0 cm), and vascular invasion was present in all patients. Technical success was achieved in all patients. Intraoperative IRE was performed in 11 (84.6%) patients, and 2 (15.4%) patients underwent percutaneous IRE. Gastrointestinal bleeding events as major complications occurred in two patients (15.4%) and, both were successfully controlled by embolization. No 60-day mortality was observed. At a median follow-up of 24.5 months (range, 9.9–33.4 months) after IRE, median OS and PFS from IRE were 20.1 and 14.5 months, respectively. IRE using clustered electrodes for LAPC appears to be a feasible therapeutic approach, offering reliable technical success and acceptable safety. Survival outcomes are encouraging; however, larger, controlled studies are required.Keywords
Funding Information
- Ministry of Health and Welfare (2024-31-1426)
This publication has 26 references indexed in Scilit:
- Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trialPancreatology, 2021
- Survival outcome after stereotactic body radiotherapy for locally advanced and borderline resectable pancreatic cancer: A systematic review and meta-analysisTranslational Oncology, 2021
- CTCAE versión 5.0. Evaluación de la gravedad de los eventos adversos dermatológicos de las terapias antineoplásicasActas Dermo-Sifiliograficas, 2021
- Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc ComparisonJournal of Vascular and Interventional Radiology, 2020
- Early nontumorous CT findings after irreversible electroporation of locally advanced pancreatic cancerAbdominal Radiology, 2016
- Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without ErlotinibJAMA, 2016
- Evaluation of thermal injury to liver, pancreas and kidney during irreversible electroporation in an in vivo experimental modelBritish Journal of Surgery, 2014
- Percutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic AdenocarcinomaJournal of Vascular and Interventional Radiology, 2012
- Irreversible Electroporation for the Ablation of Liver TumorsArchives of Surgery, 2012
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009